Viralytics raises $4.7m to fund melanoma trial
Tuesday, 20 December, 2011
Viralytics has announced it has raised $4.7 million in a share purchase plan, which has raised the company’s cash reserves to over $8 million.
The fund raising was undertaken to coincide with the commencement of patient enrolment in the company’s US-based phase II melanoma trial.
The issue price of the shares was 30.84c and was based on the five day volume weighted price as of 14 December.
Viraltyics’ (ASX:VLA) share price dropped 5.5% to 34c by mid-afternoon, down from 36c at Monday’s close.
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
Widespread resistance to common antibiotics is increasing: WHO
Increasing resistance to essential antibiotics poses a growing threat to global health, with one...
Dopamine helps our brains to let go of memories
In a discovery that could reshape how we think about memory, researchers at Flinders University...
